secwatch.observer — SEC 8-K summary
======================================

Issuer:     Atea Pharmaceuticals, Inc. (AVIR)
CIK:        0001593899
Form:       8-K
Filed at:   2026-05-12T20:17:39+00:00
Accession:  0001193125-26-219507
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Atea Q1 net loss $45.4M ($0.57/shr); HCV Phase 3 topline mid-2026
-----------------------------------------------------------------

- Net loss $45.4M vs $34.3M YoY; R&D spend rose to $41.1M on HCV Phase 3 and HEV preclinical.
- Cash, equivalents & marketable securities $256.0M at March 31, 2026, down from $301.8M at Dec 2025.
- C-BEYOND HCV Phase 3 (North America) enrollment completed; topline results expected mid-2026.
- C-FORWARD HCV Phase 3 (ex-North America) enrollment on track to complete mid-2026; topline around year-end 2026.
- HEV program: AT-587 selected as lead; in vitro data 30-150x more potent than sofosbuvir/ribavirin; Phase 1 initiation planned mid-2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1593899/000119312526219507/0001193125-26-219507-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1593899/000119312526219507/d12234d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-219507

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer